About us

Corporate Profile

APEIRON is a privately-held European biotech company based in the heart of Europe, in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory treatments.

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Investors

Apeiron’s investor base comprises mainly national and pharmaceutical companies, national and international private investors as well as the APEIRON management.

Furthermore, Apeiron has received or is entitled to get financial support from various Austrian and European support agencies.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Austria Wirtschaftsservice (AWS)
vienna business agency
Österreichische Forschungsförderungsgesellschaft (FFG)
European Investment Bank (EIB)